Telix (ASX:TLX) has announced that the first patient has been dosed in an early access program in the Netherlands for its investigational positron emission tomography (PET) imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC).
It is the most common and aggressive form of kidney cancer.
Under the program, physicians in the Netherlands may seek individual access to TLX250-CDx for use in PET characterisation of renal masses as ccRCC. The first patient was dosed at Radboud University Medical Centre in Nijmegen.
According to Professor Dr Peter Mulders from Radboud University Medical Centre in the Netherlands, a principal investigator on Telix’s completed ZIRCON trial, “Continued access to this investigational imaging agent is critically important. The detection of ccRCC in the early stages of disease can often be challenging, and reliant on invasive biopsy and nephrectomy (kidney removal). It is therefore extremely good news that TLX250-CDx, which offers a non-invasive option – or ‘molecular biopsy’ – is now available in the Netherlands on a named patient basis.”
Telix Medical director for the Europe, Middle East and Africa (EMEA) region, Frédéric Fantino, added, “The first patient dosed in this European named patient program is a significant step for Telix to support continued unmet patient need and educate key opinion leaders on the potential of TLX250-CDx to change standard of care in the diagnosis and management of ccRCC. The ZIRCON study has shown this imaging agent to be highly sensitive and specific in the detection of ccRCC, where existing imaging techniques are sometimes inconclusive.”
